With grey areas aplenty, India's marketing code in autopilot?
This article was originally published in Scrip
Ambiguities in India's new Uniform Code of Pharmaceuticals Marketing Practices (UCPMP) appear to have stretched early compliance deadlines via autopilot mode.
You may also be interested in...
India's uniform code for pharmaceuticals marketing practices, so far voluntary in nature, appears to be on course to becoming "statutory" and "mandatory", signaling some potential short-term turbulence in the growing domestic market.
Lilly brings challenger Natco into licensee fold for baricitinib in COVID-19, while the Indian firm retracts a compulsory licensing application for the JAK inhibitor, rapidly diffusing a potentially difficult situation for both sides. But will the six other baricitinib licensees in India match the price of Natco’s on-market version?
Dr Reddy’s initiates pilot roll-out of imported Russian vaccine Sputnik V, currently priced at about $13.50 per dose in India, and indicates that it hopes to bring the single-dose version Sputnik Light to the country. The Indian company also strikes a deal with a Chinese firm for a CAR-T cell therapy, an area where it hopes to “pick up skills”.